Century Therapeutics, Inc. (NasdaqCM: IPSC)
Health Care · Biotechnology · US
$1.46
-1.02% today · +167.3% 1Y
Century Therapeutics, Inc. (NasdaqCM: IPSC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $266.18M and employs 78 people.
Over the last twelve months the share price has gained 167.3%, trading between 0.44 and 3.04.
Tweenvest scores Century Therapeutics, Inc. across four factors: quality 37/100, value 65/100. Its strongest factor is value.
IPSC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $266.18M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -0.77
- Dividend yield
- —
- Beta (5Y)
- 1.67
- 52-week high
- $3.04
- 52-week low
- $0.44
- Avg volume (3M)
- —
- Shares outstanding
- 181.08M
- Employees
- 78
- Next earnings
- —
About Century Therapeutics, Inc.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
- ISIN
- US15673T1007
- Founded
- 2018
- Listed since
- Jun 18, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Bicycle Therapeutics plcNasdaqGS: BCYC | $272.27M | $3.80 | -2.44% |
| SAB Biotherapeutics, Inc.NasdaqCM: SABS | $271.14M | $2.83 | -5.03% |
| Palisade Bio, Inc.NasdaqCM: PALI | $268.38M | $1.60 | +3.90% |
| Northwest Biotherapeutics, Inc.OTCPK: NWBO | $267.79M | $0.16 | +2.15% |
| Mabpharm LimitedSEHK: 2181 | $265.39M | HK$0.51 | +3.06% |
| BridgeBio Oncology Therapeutics, Inc.NasdaqGM: BBOT | $265.38M | $3.25 | -1.81% |
| Lexeo Therapeutics, Inc.NasdaqGM: LXEO | $265.00M | $3.08 | -4.64% |
| Inventage Lab, Inc.KOSDAQ: A389470 | $263.31M | ₩26,600.00 | -6.01% |
Figures last refreshed Oct 11, 2026.